Adding lanreotide to everolimus significantly prolonged progression-free survival compared with everolimus alone in patients ...

I recently was invited to give a presentation about genomic alterations in AML at the 2024 ASTCT Clinical Education Conference for advanced practice providers, nurses and fellows.I was pleased to have ...

The BCCI medical team remains in close consultation with their New Zealand counterparts, and any potential travel to New ...

Riyadh, The Kingdom of Saudi Arabia: Takeda, the global biopharmaceutical company, is pleased to announce a new strategic ...

First-line treatment with targeted therapies plus chemotherapy offered overall response benefits in BRAF V600E-mutant ...

The Japanese pharma had one asset rejected by the FDA and withdrew a regulatory application for another, but already this ...

Naporafenib is Erasca’s main candidate, and it has Fast Track status for NRASm melanoma. See why I rate ERAS stock as a buy.

The drugmaker sees additional growth opportunities in ophthalmology and neuromuscular disorders, Chief Medical Officer ...

A data analysis from a randomized clinical trial for stage 3 colon cancer patients by investigators at Dana-Farber Brigham ...

More than 600 people signed up for St Joseph’s Medical Center’s 16th Run/Walk for Wellness, exceeding the cancer institute ...

Dividend stocks can be a great way to boost your portfolio's growth potential or provide a form of passive income over the years. While not all dividend stocks are the same, finding great companies ...

In last year's update, AbbVie raised the combined 2027 net sales guidance for Skyrizi and Rinvoq by $6 billion to $27 billion ...